1/26/2024 6:34:15 PM - Y - Posted a gain today backed by +36% above average volume for its second-best-ever close. The recent low ($103.38 on 1/23/24) defines important near-term support nearly coinciding with its 50 DMA line ($102.64).
1/24/2024 6:54:17 PM - Y - Volume was light today while consolidating near its all-time high, testing prior highs in the $105 area that define initial support above its 50 DMA line ($102.40).
1/17/2024 5:21:06 PM - Y - Volume has been cooling after recently challenging its all-time high. Prior highs in the $105 area define initial support above its 50 DMA line ($101.85).
1/11/2024 12:23:23 PM - Y - Pulling back today after challenging its all-time high. Prior highs in the $105 area define initial support above its 50 DMA line ($101.34).
1/9/2024 5:22:46 PM - Y - Stubbornly holding its ground since a 1/04/24 gap up and volume-driven gain triggered a technical buy signal while hitting a new all-time high. Prior highs in the $105 area define initial support above its 50 DMA line ($100.84).
1/5/2024 5:13:14 PM - Y - Pulled back today with average volume. Gap up and volume-driven gain on the prior session triggered a technical buy signal while hitting a new all-time high. Prior highs in the $105 area define initial support above its 50 DMA line ($100.42) See the latest FSU analysis for more details and a new annotated graph.
1/4/2024 12:41:01 PM - Y - Gapped up today and it is hitting a new all-time high. Recently wedged toward its high with gains lacking great volume conviction. Its 50 DMA line ($100) defines initial support above the recent low ($94.73 on 12/11/23) on pullbacks.
12/28/2023 6:21:31 PM - Y - There was a "negative reversal" after an early gain today as, with light volume, it closed at the session low. Recently wedged above its 50 DMA line ($99.75) toward its high with gains lacking great volume conviction. Its 50 DMA line defines initial support above the recent low ($94.73 on 12/11/23) on pullbacks.
12/21/2023 4:58:05 PM - Y - Posted a 4th consecutive gain today, wedging further above its 50 DMA line ($99.59) toward its high. Its 50 DMA line defines initial support above the recent low ($94.73 on 12/11/23) on pullbacks.
12/18/2023 7:24:56 PM - Y - Gapped up today and closed the session near its 50 DMA line ($99.17). Recent low ($94.73 on 12/11/23) defines important near-term support to watch on pullbacks.
12/13/2023 5:46:21 PM - Y - Color code is changed to yellow after it rebounded and closed the session just above the 50 DMA line ($98.72) helping its outlook to improve.
12/11/2023 10:06:22 PM - G - Managed a "positive reversal" today but remains below its 50 DMA line ($98.41). A rebound above the 50 DMA line is needed for its outlook to improve.
12/6/2023 5:49:56 PM - G - Color code is changed to green as it slumped below its 50 DMA line ($98.09) with today's loss backed by light volume. A prompt rebound above the 50 DMA line is needed for its outlook to improve. It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
12/1/2023 10:07:59 PM - Y - Pulled back from its 52-week high with losses this week. Its 50 DMA line ($97.61) defines near-term support to watch. It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
11/28/2023 12:35:59 PM - Y - Pulling back from its 52-week high with today's gap down. Found prompt support at its 50 DMA line ($97.11) when recently consolidating. It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
11/27/2023 5:04:22 PM - Y - Pulled back from its 52-week high with today's loss on average volume. Found prompt support at its 50 DMA line ($97) when recently consolidating. It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
11/27/2023 12:52:21 PM - Y - Perched at its 52-week high today following recent gains with near average volume. Found prompt support at its 50 DMA line ($97) when recently consolidating. It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
11/24/2023 12:21:06 PM - Y - Hitting a new 52-week high with today's gain. Found prompt support last week at its 50 DMA line ($96.77). It has been repeatedly noted - "Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal."
11/22/2023 5:03:42 PM - Y - Stubbornly holding its ground perched only -0.7% off its 52-week high. Found prompt support last week at its 50 DMA line ($96.60). Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal.
11/20/2023 6:36:07 PM - Y - Closed at the session high today with a 3rd consecutive gain leaving it perched only -0.4% off its 52-week high. Found prompt support last week at its 50 DMA line ($96.37). Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal.
11/16/2023 4:43:45 PM - Y - Gapped up today following 3 consecutive losses, finding prompt support at its 50 DMA line ($96.22). It remains perched only -4.3% off its 52-week high. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal. More damaging losses would raise concerns.
11/15/2023 5:32:39 PM - Y - Pulled back today for a 3rd consecutive loss with above-average volume, testing its 50 DMA line ($96.18). It remains perched only -7.3% off its 52-week high. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal. More damaging losses would raise concerns.
11/14/2023 6:19:37 PM - Y - Recently churning above-average volume while consolidating above its 50 DMA line ($96.17) and ending the session perched only -4.6% off its 52-week high. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal.
11/13/2023 12:51:52 PM - Y - Managed a "positive reversal" after early weakness today while again churning above-average volume. Its 50 DMA line ($96.09) defines important near-term support to watch on pullbacks. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal.
11/10/2023 5:18:22 PM - Y - Posted a small gain today while churning above-average volume. Its 50 DMA line ($95.96) defines important near-term support to watch on pullbacks. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal.
11/8/2023 1:09:22 PM - Y - Churning above average volume today after recently wedging higher with gains lacking great volume conviction. Its 50 DMA line ($95.65) defines important near-term support to watch on pullbacks. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal. This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. Reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter, well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady.
11/7/2023 7:05:23 PM - Y - Posted a gain with near-average volume for its second-best-ever close. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal. This Denmark-based Medical - Ethical Drugs firm found support after briefly undercutting its 50 DMA line in recent weeks. Shares split 2-1 on 9/20/23. Reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter, well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady.
11/3/2023 4:45:53 PM - Y - Gapped down today for a loss with lighter volume. Subsequent gains for new highs backed by at least +40% above average volume are needed to trigger a technical buy signal. This Denmark-based Medical - Ethical Drugs firm found support after briefly undercutting its 50 DMA line in recent weeks. Shares split 2-1 on 9/20/23. Reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter, well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady.
11/2/2023 12:58:14 PM - Y - Color code is changed to yellow with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. Subsequent gains for new highs backed by at least +40% above averqage volume are needed to trigger a technical buy signal. This Denmark-based Medical - Ethical Drugs firm gapped up today challenging its all-time high. Found support after briefly undercutting its 50 DMA line in recent weeks. Shares split 2-1 on 9/20/23. Reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter. well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady.
10/19/2023 12:36:30 PM - This Denmark-based Medical - Ethical Drugs firm gapped down today, pulling back from its all-time high. Found support after briefly undercutting its 50 DMA line when noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/16/2023 12:47:06 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back today after hitting new all-time highs with 4 consecutive volume-driven gains. Found support after briefly undercutting its 50 DMA line when noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/13/2023 12:41:30 PM - This Denmark-based Medical - Ethical Drugs firm is hitting new all-time highs with today's 4th consecutive volume-driven gain. Found support after briefly undercutting its 50 DMA line when noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/12/2023 12:40:28 PM - This Denmark-based Medical - Ethical Drugs firm gapped up again today hitting a new all-time high. Found suport after briefly undercutting its 50 DMA line when noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/11/2023 12:46:51 PM - This Denmark-based Medical - Ethical Drugs firm gapped up today challenging its all-time high. Found suport after briefly undercutting its 50 DMA line when noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/5/2023 1:00:30 PM - This Denmark-based Medical - Ethical Drugs firm has been pulling back from its all-time high. Violated its 50 DMA line ($91.06) with a gap down when last noted with caution in the 10/03/23 mid-day report - "Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
10/3/2023 12:33:04 PM - This Denmark-based Medical - Ethical Drugs firm has been pulling back from its all-time high and violated its 50 DMA line ($90.68) with a gap down. Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/28/2023 1:01:26 PM - This Denmark-based Medical - Ethical Drugs firm pulled back from its all-time high and is consolidating above its 50 DMA line ($90.20). Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/21/2023 12:39:37 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back from its all-time high toward its 50 DMA line ($89) with noted volume-driven losses. Shares split 2-1 on 9/20/23. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/20/2023 12:21:56 PM - This Denmark-based Medical - Ethical Drugs firm is still consolidating near its all-time high following noted volume-driven losses. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/18/2023 12:56:50 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back from its all-time high with recent volume-driven losses. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/13/2023 12:40:28 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back from its all-time high hit on Monday after 6 consecutive volume-driven gains. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/12/2023 12:38:39 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back from its all-time high hit on the prior session after 6 consecutive volume-driven gains. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/11/2023 12:34:45 PM - This Denmark-based Medical - Ethical Drugs firm is perched at its all-time high and on track today for a 6th consecutive volume-driven gain. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/8/2023 12:22:26 PM - This Denmark-based Medical - Ethical Drugs firm is perched at its all-time high and on track today for a 5th consecutive volume-driven gain. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
9/7/2023 12:33:48 PM - This Denmark-based Medical - Ethical Drugs firm is hitting a new all-time high with today's 4th consecutive volume-driven gain. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
8/16/2023 12:33:23 PM - This Denmark-based Medical - Ethical Drugs firm is consolidating after a considerable gap up on 8/08/23 hitting a new all-time high. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
8/15/2023 12:46:57 PM - This Denmark-based Medical - Ethical Drugs firm is consolidating after a considerable gap up on 8/08/23 hitting a new all-time high. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
8/14/2023 1:00:14 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back for a 4th small volume-driven loss today, consolidating after a considerable gap up on 8/08/23 hitting a new all-time high. Reported Jun '23 quarterly earnings +53% on +37% sales revenues versus the year-ago period, its 2nd strong quarter. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
8/11/2023 1:06:27 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back for a 3rd volume-driven loss today, consolidating after a considerable gap up on 8/08/23 hitting a new all-time high. Due to report Jun '23 quarterly results. Noted in prior mid-day reports - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
8/10/2023 12:31:33 PM - This Denmark-based Medical - Ethical Drugs firm is consolidating after a considerable gap up on 8/08/23 hitting a new all-time high. Due to report Jun '23 quarterly results. Noted in prior mid-day reports - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
8/9/2023 12:42:10 PM - This Denmark-based Medical - Ethical Drugs firm gapped up on the prior session hitting a new all-time high. Due to report Jun '23 quarterly results. Noted in the 7/12/23 mid-day report - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
8/8/2023 1:00:10 PM - This Denmark-based Medical - Ethical Drugs firm gapped up today hitting a new all-time high. Last noted in the 7/12/23 mid-day report - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
7/12/2023 12:32:19 PM - This Denmark-based Medical - Ethical Drugs firm met resistance near its 50 DMA line ($162) and slumped further in recent weeks since noted with caution near its all-time high in the 5/08/23 mid-day report - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
7/11/2023 12:50:31 PM - This Denmark-based Medical - Ethical Drugs firm met resistance near its 50 DMA line ($162) and slumped further in recent weeks since noted with caution near its all-time high in the 5/08/23 mid-day report - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
6/21/2023 1:05:01 PM - This Denmark-based Medical - Ethical Drugs firm slumped below its 50 DMA line ($164.53) in recent weeks since last noted with caution near its all-time high in the 5/08/23 mid-day report - "Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria)."
5/8/2023 1:03:27 PM - This Denmark-based Medical - Ethical Drugs firm gapped up today, and it is perched within close striking distance of its all-time high. Reported Mar '23 quarterly earnings +38% on +24% sales revenues versus the year-ago period. Fundamental concerns remain. Prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria).
5/4/2023 12:59:53 PM - This Denmark-based Medical - Ethical Drugs firm gapped down today, pulling back from its all-time high following noted volume-driven gains. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/21/2023 12:22:35 PM - This Denmark-based Medical - Ethical Drugs firm is hitting another new all-time high today, adding to previously noted volume-driven gains. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/19/2023 12:44:09 PM - This Denmark-based Medical - Ethical Drugs firm is pulling back from its all-time high today following volume-driven gains. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/18/2023 12:56:56 PM - This Denmark-based Medical - Ethical Drugs firm is perched at its all-time high today following 4 consecutive volume-driven gains. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/14/2023 12:40:16 PM - This Denmark-based Medical - Ethical Drugs firm is hitting another new all-time high with today's 3rd consecutive volume-driven gain. Wedged higher in recent weeks with gains lacking great volume conviction. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line ($146.40) - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/13/2023 12:26:51 PM - This Denmark-based Medical - Ethical Drugs firm is hitting new all-time highs with today's 2nd consecutive volume-driven gain. Wedged higher in recent weeks with gains lacking great volume conviction. Found prompt support after noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line ($146.40) - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
4/12/2023 12:37:10 PM - This Denmark-based Medical - Ethical Drugs firm is hitting a new all-time high today and has been wedging higher in recent weeks with gains lacking great volume conviction. Found prompt support after last noted with caution in the 3/16/23 mid-day report when briefly undercutting its 50 DMA line ($145.84) - "Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period."
3/16/2023 12:54:49 PM - This Denmark-based Medical - Ethical Drug firm gapped down today undercutting its 50 DMA line ($139.84). Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year-ago period.
3/8/2023 12:41:55 PM - Fundamental concerns remain. Reported Dec '22 quarterly earnings +19% on +18% sales revenues versus the year ago period. This Denmark-based Medical - Ethical Drug firm found prompt support at its 50 DMA line ($139) on the recent pullback.
8/3/2022 12:41:02 PM - Due to report Jun '22 quarterly results, this Denmark-based Medical - Ethical Drug firm is abruptly violating its 50 and 200 DMA lines with today's big volume-driven loss after quietly hovering near its all-time high. Volume and volatility often increase near earnings news. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
7/18/2022 12:39:34 PM - This Denmark-based Medical - Ethical Drug firm found support near its 200 DMA line and is rebounding near its all-time high. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
7/8/2022 12:46:38 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 200 DMA line which has acted as support. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
7/6/2022 12:28:57 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
7/5/2022 12:17:25 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
6/29/2022 12:28:32 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
6/28/2022 12:41:04 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
6/23/2022 12:12:21 PM - This Denmark-based Medical - Ethical Drug firm is consolidating below its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
5/20/2022 12:16:13 PM - This Denmark-based Medical - Ethical Drug firm is consolidating below its 50 and finding support near its 200 DMA line. Prior mid-day reports cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
5/19/2022 12:24:47 PM - This Denmark-based Medical - Ethical Drug firm has slumped below its 50 and 200 DMA lines with volume-driven losses. The 5/10/22 mid-day report cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
5/10/2022 12:56:11 PM - This Denmark-based Medical - Ethical Drug firm violated its 50 DMA line ($110.60) as it gapped down on the prior session testing its 200 DMA line ($105) with volume-driven losses. Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period.
5/10/2022 12:54:53 PM - This Denmark-based Medical - Ethical Drug firm violated its 50 DMA line ($110.60) as it gapped down on the prior session testing its 200 DMA line ($105) with volume-driven losses. Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period.
5/10/2022 12:54:10 PM - This Denmark-based Medical - Ethical Drug firm violated its 50 DMA line ($110.60) as it gapped down on the prior session testing its 200 DMA line ($105) with volume-driven losses. Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period.
5/10/2022 12:53:19 PM - This Denmark-based Medical - Ethical Drug firm violated its 50 DMA line ($110.60) as it gapped down on the prior session testing its 200 DMA line ($105) with volume-driven losses. Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period.
5/9/2022 12:12:15 PM - This Denmark-based Medical - Ethical Drug firm violated its 50 DMA line ($110.54) as it gapped up today for a 3rd consecutive volume-driven loss. Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period. During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line.
4/29/2022 12:36:50 PM - This Denmark-based Medical - Ethical Drug firm tested its 50 DMA line ($109) on the prior session and gapped up today. Due to report Mar '22 quarterly results on Monday 5/04/22. Noted with caution in prior mid-day reports - "During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
4/28/2022 12:57:11 PM - This Denmark-based Medical - Ethical Drug firm is testing its 50 DMA line ($108.92) today. While consolidating since hitting its all-time high it was noted with caution in prior mid-day reports - "During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
4/12/2022 12:43:24 PM - This Denmark-based Medical - Ethical Drug firm is pulling back today following volume-driven gains to new all-time highs. Noted with caution in prior mid-day reports - "During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
4/11/2022 12:55:50 PM - This Denmark-based Medical - Ethical Drug firm has stubbornly held its ground after hitting a new all-time high with a 5th consecutive gain when noted with caution in the 4/07/22 mid-day report - "During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
4/7/2022 12:53:25 PM - This Denmark-based Medical - Ethical Drug firm gapped up today hitting a new all-time high with its 5th consecutive gain. During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
4/4/2022 12:39:08 PM - This Denmark-based Medical - Ethical Drug firm is approaching its 52-week and all-time highs. During a three and a half month consolidation it found prompt support near its 200 DMA line and has made steady progress above its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
3/11/2022 12:20:14 PM - This Denmark-based Medical - Ethical Drug firm has found prompt support near its 200 DMA line ($99.71) and has been consolidating above its 50 DMA line. Prior mid-day reports cautioned members - "Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
3/10/2022 1:08:31 PM - This Denmark-based Medical - Ethical Drug firm has found prompt support near its 200 DMA line ($99.59) and rebounded above its 50 DMA line again with this week's volume-driven gains. Prior mid-day reports cautioned members - "Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain."
3/9/2022 12:43:56 PM - This Denmark-based Medical - Ethical Drug firm has found prompt support near its 200 DMA line ($99.47) and is rebounding above its 50 DMA line again with this week's volume-driven gains. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain.
3/8/2022 12:52:38 PM - This Denmark-based Medical - Ethical Drug firm has found prompt support near its 200 DMA line ($99) and is rebounding above its 50 DMA line again with today's big gain. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain.
2/2/2022 12:37:33 PM - This Denmark-based Medical - Ethical Drug firm found prompt support near its 200 DMA line ($96.42) and is rebounding above its 50 DMA line with today's 5th consecutive gain. Reported earnings +11% on +11% sales revenues for the Dec '21 quarter versus the year ago period. Fundamental concerns remain.
9/30/2020 12:25:43 PM - This Denmark-based Medical - Ethical Drug firm is perched near its all-time high after a volume-driven gain on the prior session. Near-term support to watch is at its 50 DMA line ($66.79). Reported earnings +11% on -1% sales revenues for the Jun '20 quarter versus the year ago period. Fundamental concerns remain.
7/1/2020 12:32:50 PM - This Denmark-based Medical - Ethical Drug firm paused after hitting a new all-time high last week. Consolidation above support at its 50 DMA line ($64.74). Reported earnings +14% on +14% sales revenues for the Mar '20 quarter. Fundamental concerns remain.
6/16/2020 1:01:10 PM - This Denmark-based Medical - Ethical Drug firm paused after hitting a new all-time high last week. Consolidation above support at its 50 DMA line. Reported earnings +14% on +14% sales revenues for the Mar '20 quarter. Fundamental concerns remain.
6/15/2020 12:26:54 PM - This Denmark-based Medical - Ethical Drug firm paused after hitting a new all-time high last week. Consolidation above support at its 50 DMA line. Reported earnings +14% on +14% sales revenues for the Mar '20 quarter. Fundamental concerns remain.
6/10/2020 12:51:26 PM - This Denmark-based Medical - Ethical Drug firm gapped up today hitting a new all-time high after a consolidation above support at its 50 DMA line. Reported earnings +14% on +14% sales revenues for the Mar '20 quarter. Fundamental concerns remain.
8/7/2015 1:17:15 PM - This Denmark-based Medical - Ethical Drug firm gapped down on the prior session. Volume-driven losses while retreating from its all-time high are testing support at its 50 DMA line. Reported earnings -2% on +2% sales revenues for the Jun '15 quarter. Noted with caution in prior mid-day reports - "Prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
8/6/2015 12:58:41 PM - This Denmark-based Medical - Ethical Drug firm gapped down today for a volume-driven loss, retreating from its all-time high toward its 50 DMA line. Noted with caution in the 7/17/15 mid-day report - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
7/31/2015 1:11:11 PM - This Denmark-based Medical - Ethical Drug firm stalled at its all-time high after rebounding from below its 50 DMA line. Last noted with caution in the 7/17/15 mid-day report - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
7/17/2015 12:39:19 PM - This Denmark-based Medical - Ethical Drug firm is perched at its all-time high after rebounding from below its 50 DMA line. Noted with caution in prior mid-day reports - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
6/30/2015 1:37:14 PM - This Denmark-based Medical - Ethical Drug firm is still sputtering below its 50 DMA line. Noted with caution in prior mid-day reports - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
6/29/2015 1:56:02 PM - This Denmark-based Medical - Ethical Drug firm is still sputtering below its 50 DMA line. Noted with caution in prior mid-day reports - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
6/17/2015 1:07:10 PM - This Denmark-based Medical - Ethical Drug firm slumped below its 50 DMA line during a quiet streak of 5 consecutive losses from its all-time high. Last noted with caution in the 6/10/15 mid-day report while tallying a volume-driven gain - "Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history."
6/10/2015 1:24:14 PM - This Denmark-based Medical - Ethical Drug firm found support near its 50 DMA line and gapped up today, hitting a new high with its considerable volume-driven gain. Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history.
6/9/2015 12:45:52 PM - This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 DMA line. Reported earnings +22% on -3% sales revenues for the Mar '15 quarter, and prior quarterly comparisons showed earnings below the +25% guideline (C criteria) with sub par sales revenues growth. A slight downturn in FY '14 hurt its good annual earnings (A criteria) history.
10/24/2014 12:40:43 PM - This Denmark-based Medical - Ethical Drug firm has encountered resistance at its 50 DMA line this week while rebounding after recently undercutting its 200 DMA line. Noted with caution in prior mid-day reports - "Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth."
10/21/2014 12:55:38 PM - This Denmark-based Medical - Ethical Drug firm is rebounding after undercutting its 200 DMA line during its consolidation since last noted with caution in the 10/03/14 mid-day report - "Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth."
10/3/2014 12:03:39 PM - This Denmark-based Medical - Ethical Drug firm is consolidating -3.3% off its 52-week high and enduring distributional pressure this week. Rebounded from below its 50 DMA line since noted with caution in the 9/02/14 mid-day report. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth.
10/2/2014 12:39:03 PM - Consolidating -3.6% off its 52-week high and enduring distributional pressure with a loss today on higher volume. Rebounded from below its 50 DMA line since noted with caution in the 9/02/14 mid-day report. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 206 in Sep '13 to 202 in Jun '14, not a good sign concerning the I criteria.
9/18/2014 12:29:20 PM - Gapped up hitting a new 52-week high with today's 9th gain in the span of 10 sessions marked by ever-increasing volume. Rebounded from below its 50 DMA line since noted with caution in the 9/02/14 mid-day report. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 206 in Sep '13 to 202 in Jun '14, not a good sign concerning the I criteria.
9/12/2014 12:31:06 PM - Challenging its 52-week high with today's gap up and 6th consecutive gain. Rebounded from below its 50 DMA line since noted with caution in the 9/02/14 mid-day report. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter a 4th consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 206 in Sep '13 to 202 in Jun '14, not a good sign concerning the I criteria.
9/2/2014 12:37:46 PM - Slumping below its 50 DMA line with higher volume behind today's loss. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/21/2014 12:30:35 PM - Encountering resistance near its 50 DMA line. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/14/2014 12:45:56 PM - Still sputtering below its 50 DMA line since gaping down on 8/07/14 for a volume-driven loss. Reported earnings +22% on +7% sales revenues for the Jun '14 quarter. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/7/2014 12:34:04 PM - Violated its 50 DMA line with a gap down today for a volume-driven loss. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/5/2014 12:02:10 PM - Found support at its 50 DMA line this week, tallying volume-driven gains. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/4/2014 12:53:26 PM - Endured distributional pressure and tested support at its 50 DMA line on the prior session. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
8/1/2014 12:26:32 PM - Enduring more distributional pressure and slumping below its 50 DMA line today. Prior mid-day reports repeatedly cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
7/29/2014 12:44:49 PM - Endured distributional pressure recently while consolidating above its 50 DMA line, perched within striking distance of its 52-week high. Prior mid-day reports cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
7/9/2014 12:27:16 PM - Enduring distributional pressure this week while consolidating above its 50 DMA line, perched within striking distance of its 52-week high. Prior mid-day reports cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
6/23/2014 12:33:33 PM - Consolidating above its 50 DMA line within striking distance of its 52-week high. Prior mid-day reports cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
6/13/2014 12:27:24 PM - Consolidating above its 50 DMA line. The 6/11/14 mid-day report cautioned members - "Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria."
6/11/2014 12:43:28 PM - Enduring distributional pressure today. Reported earnings +18% on +9% sales revenues for the Mar '14 quarter, a 3rd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 216 in Jun '13 to 208 in Mar '14, not a good sign concerning the I criteria.
3/25/2014 2:01:29 PM - Enduring distributional pressure in recent weeks. When hitting its 52-week high with a volume-driven gain the 2/25/14 mid-day report cautioned members - "Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria."
3/3/2014 12:51:59 PM - Pulling back from new all-time highs hit last week after 6 consecutive weekly gains. The 2/25/14 mid-day report cautioned members - "Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria."
2/25/2014 12:20:54 PM - Powering to another new all-time high with a gap up gain today, on track for its 6th consecutive weekly gain. Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria.
2/21/2014 12:36:24 PM - Perched at its all-time high today tallying another volume-driven gain, on track for its 5th consecutive weekly gain. Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria.
2/19/2014 1:08:26 PM - Perched at its all-time high today following another volume-driven gain, on track for its 5th consecutive weekly gain. Reported earnings +14% on +8% sales revenues for the Dec '13 quarter, a 2nd consecutive quarterly comparison with earnings below the +25% guideline (C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm has seen the number of top-rated funds owning its shares fall from 232 in Mar '13 to 200 in Dec '13, not a good sign concerning the I criteria.
2/6/2013 12:36:30 PM - Perched at its all-time high today with another volume-driven gain, on track for its 7th consecutive weekly gain. Reported earnings +27% on +17% sales revenues for the Dec '12 quarter, a 2nd quarter with earnings above the +25% guideline. The 4 prior quarterly comparisons had earnings increases below the +25% guideline (not meeting the C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 193 in Dec '11 to 213 in Dec '12, a reassuring sign concerning the I criteria.
1/16/2013 12:17:20 PM - Hitting a new all-time high today with its 9th consecutive gain. Reported earnings +34% on +15% sales revenues for the Sep '12 quarter. The 4 prior quarterly comparisons had earnings increases below the +25% guideline (not meeting the C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 193 in Dec '11 to 213 in Dec '12, a reassuring sign concerning the I criteria.
11/16/2012 12:26:38 PM - Consolidating after considerable volume-driven losses led to an abrupt retreat from all-time highs to its 200 DMA line which acted as support last week. Reported earnings +34% on +15% sales revenues for the Sep '12 quarter. The 4 prior quarterly comparisons had earnings increases below the +25% guideline (not meeting the C criteria). It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 193 in Dec '11 to 221 in Sep '12, a reassuring sign concerning the I criteria.
10/25/2012 12:20:17 PM - Down today for a considerable loss on heavy volume, retreating abruptly from all-time highs hit earlier this week. Trading near its 50 DMA line which acted as support when recently consolidating. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
10/22/2012 12:41:39 PM - Making a 2nd consecutive mid-day report appearance while tallying a 2nd consecutive gain with above average volume for a new all-time high. Found support near its 50 DMA line when recently consolidating. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
10/19/2012 12:59:45 PM - Gain with above average volume today for a new all-time high. Found support near its 50 DMA line when recently consolidating. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
9/28/2012 12:24:24 PM - Perched near all-time highs and quietly consolidating above its 50 DMA line. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
9/17/2012 12:23:06 PM - Pulled back from near all-time highs and slumped toward its 50 DMA line while encountering some distributional pressure last week. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
9/14/2012 12:23:17 PM - Pulling back from near all-time highs and slumping toward its 50 DMA line while encountering some distributional pressure this week. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
9/13/2012 12:36:12 PM - Pulled back from near all-time highs and slumped toward its 50 DMA line while encountering some distributional pressure this week. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
9/12/2012 12:28:45 PM - Small gap down today, pulling back from near all-time highs and slumping toward its 50 DMA line while encountering some distributional pressure. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
8/22/2012 12:32:12 PM - Still hovering near its all-time high today, encountering some distributional pressure this week. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
8/21/2012 12:24:24 PM - Hovering near its all-time high today. Its 4 latest quarterly comparisons through Jun '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
8/9/2012 1:06:40 PM - Perched near its all-time high today. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
8/3/2012 12:40:38 PM - Today's gain has it rallying into new all-time high territory. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/20/2012 1:08:35 PM - Rebounded above its 50 DMA line in recent weeks and it is now consolidating in a tight trading range for the past few weeks, today perched only -3.3% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/18/2012 12:48:27 PM - Rebounded above its 50 DMA line in recent weeks and it is now perched -2.8% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/13/2012 12:33:21 PM - Rebounded above its 50 DMA line in recent weeks and it is now perched -3.9% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/9/2012 12:15:07 PM - Rebounded above its 50 DMA line in recent weeks and it is now perched -3.6% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/6/2012 12:03:47 PM - Rebounded above its 50 DMA line last week and it is now perched -3.9% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
5/24/2012 12:17:54 PM - Churned heavy volume while its 50 DMA line acted as a resistance level in the past week. Perched -8.1% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
5/22/2012 12:18:19 PM - Churning heavy volume today after a volume-driven gain on the prior session helped it rally near its 50 DMA line which may now act as a resistance level. Perched -5% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
5/21/2012 12:55:27 PM - Volume-driven gain today, rallying near its 50 DMA line which may now act as a resistance level. Perched -5% off its all-time high. Its 3 latest quarterly comparisons through Mar '12 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
4/27/2012 12:40:03 PM - Gapped down today, and a volume-driven loss has it sinking near its 50 DMA line, retreating from the all-time high hit last week. The 4/03/12 mid-day report noted- "Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - 'It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria.'"
4/17/2012 12:35:12 PM - Up today for a 5th consecutive gain, challenging its all-time high hit when noted in the 4/03/12 mid-day report - "Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - 'It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria.'"
4/4/2012 12:33:29 PM - Gapped down today, slumping below prior highs after 2 prior gap up gains cleared an orderly flat base above its 50 DMA line and hit new all-time highs. Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
4/3/2012 12:09:07 PM - Second consecutive gap up today, clearing an orderly flat base above its 50 DMA line and hitting a new all-time high. Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
2/29/2012 12:30:24 PM - Small gap down with above average volume today, pulling back from an all-time high quietly hit on the prior session. Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (not meeting the C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
2/7/2012 12:25:54 PM - Considerable gap up gain today for a new all-time high today, posting its 6th consecutive gain. Its 2 latest quarterly comparisons through Dec '11 had earnings increases below the +25% guideline (bad C criteria). It went through a deep consolidation below its 200 DMA line then rebounded since last noted in the 7/28/11 mid-day report. - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
7/28/2011 1:06:08 PM - Consolidating near its 50 DMA line and perched -7% off its all-time high today. Found support at its 200 DMA line during its consolidation since last noted in the 6/10/11 mid-day report - "Reported earnings +31% on +20% sales revenues for the quarter ended March 31, 2011, so its 3 latest quarterly comparisons have earnings increases above the +25% guideline (C criteria) . It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria."
6/10/2011 12:03:11 PM - Consolidating under its 50 DMA line which has acted as resistance in the weeks since violated by a 5/05/11 gap down on high volume. Subsequent gains above the 50 DMA line and its recent high ($127.95 on 6/06/11) would help its outlook, technically. Reported earnings +31% on +20% sales revenues for the quarter ended March 31, 2011, so its 3 latest quarterly comparisons have earnings increases above the +25% guideline (C criteria) . It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 204 in Mar '11, a reassuring sign concerning the I criteria.
5/24/2011 12:34:23 PM - It has not formed a sound base pattern and its 50 DMA line was violated by a 5/05/11 gap down on high volume. That short-term average has subsequently acted as resistance, while gains above it would help its outlook, technically. Reported earnings +31% on +20% sales revenues for the quarter ended March 31, 2011, so its 3 latest quarterly comparisons have earnings increases above the +25% guideline (C criteria) . It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 209 in Mar '11, a reassuring sign concerning the I criteria.
4/29/2011 1:45:20 PM - It has not formed a sound base and is consolidating -4.0% off its all-time high today, above its 50 DMA line which acted as support throughout its ongoing ascent. Reported earnings +31% on +20% sales revenues for the quarter ended March 31, 2011, so its 3 latest quarterly comparisons have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 197 in Mar '11, a reassuring sign concerning the I criteria.
4/28/2011 1:25:13 PM - It has not formed a sound base and is consolidating -4.7% off its all-time high today, testing its 50 DMA line which acted as support throughout its ongoing ascent. Reported earnings +31% on +20% sales revenues for the quarter ended March 31, 2011, so its 3 latest quarterly comparisons have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 196 in Mar '11, a reassuring sign concerning the I criteria.
4/18/2011 1:03:55 PM - It has not formed a sound base and is consolidating -3.4% off its all-time high today, above support at its 50 DMA line which acted as support throughout its ongoing ascent. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 196 in Dec '10, a reassuring sign concerning the I criteria.
3/31/2011 12:52:33 PM - Gains this week have it quietly approaching its all-time high. It has been consolidating for 4 weeks and found great support near its 50 DMA line throughout its ongoing ascent. It now faces little resistance due to overhead supply. Last noted in the 3/11/11 mid-day report - "Disciplined investors may watch for a proper new base or secondary buy point to develop which may subsequently be noted. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 185 in Dec '10, a reassuring sign concerning the I criteria."
3/11/2011 1:03:56 PM - Hovering near its all-time high following a recently noted spurt of volume-driven gains. It found great support near its 50 DMA line throughout its ongoing ascent. It now faces no resistance due to overhead supply, but it is not near a sound base pattern. Disciplined investors may watch for a proper new base or secondary buy point to develop which may subsequently be noted. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 185 in Dec '10, a reassuring sign concerning the I criteria.
3/8/2011 12:32:17 PM - Perched near its all-time high following a recently noted spurt of volume-driven gains. Found great support near its 50 DMA line throughout its ongoing ascent. It now faces no resistance due to overhead supply, but it is not near a sound base pattern. Disciplined investors may watch for a proper new base or secondary buy point to develop which may subsequently be noted. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 184 in Dec '10, a reassuring sign concerning the I criteria.
3/1/2011 12:38:55 PM - Perched near its all-time high following a recently noted spurt of volume-driven gains. Found great support near its 50 DMA line throughout its ongoing ascent. It now faces no resistance due to overhead supply, but it is not near a sound base pattern. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 185 in Dec '10, a reassuring sign concerning the I criteria.
2/22/2011 1:17:07 PM - Gapped down today, pulling back from the new high hit on the prior session. Posted 10 volume-driven gains in the past 11 sessions while rallying to all-time highs. Found great support near its 50 DMA line throughout its ongoing ascent, but it is not near a sound base now. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 184 in Dec '10, a reassuring sign concerning the I criteria.
2/18/2011 1:35:41 PM - Gapped up for a new high today after pausing in a tight trading range following 7 consecutive volume-driven gains to all-time high territory. Found great support near its 50 DMA line throughout its ongoing ascent, but it is not near a sound base now. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 184 in Dec '10, a reassuring sign concerning the I criteria.
2/17/2011 1:06:35 PM - Recently paused in a tight trading range following 7 consecutive volume-driven gains to all-time high territory. Found great support near its 50 DMA line throughout its ongoing ascent. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, so 3 of the 4 latest quarterly comparisons now have earnings increases above the +25% guideline. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. This Denmark-based Medical - Ethical Drug firm also has seen the number of top-rated funds owning its shares rise from 152 in Mar '10 to 184 in Dec '10, a reassuring sign concerning the I criteria.
2/16/2011 12:31:43 PM - Paused following 7 consecutive volume-driven gains to new all-time highs. Recently found support above its 50 DMA line. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, yet the 2/02/11 mid-day report and earlier reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
2/15/2011 12:39:17 PM - Small gap down today following 7 consecutive volume-driven gains to new all-time highs after finding support above its 50 DMA line. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, yet the 2/02/11 mid-day report and earlier reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
2/14/2011 1:08:26 PM - After consolidating above its 50 DMA line, a gap up today for a 7th consecutive volume-driven gain has it surging to new all-time highs. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, yet the 2/02/11 mid-day report and earlier reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
2/11/2011 1:16:30 PM - After consolidating above its 50 DMA line, a 6th consecutive volume-driven gain today has it inching to another new all-time high. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, yet the 2/02/11 mid-day report and earlier reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
2/10/2011 1:38:16 PM - After consolidating above its 50 DMA line, a 5th consecutive volume-driven gain today helped it touch a new all-time high. Reported earnings +63% on +15% sales revenues for the quarter ended December 31, 2010, yet the 2/02/11 mid-day report and earlier reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
2/2/2011 1:06:52 PM - Consolidating above its 50 DMA line only -4.2% off its all-time high. Prior mid-day reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
1/19/2011 12:57:44 PM - Pulling back today after a gap up gain with above average volume for a new all-time high yesterday. Prior mid-day reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
1/18/2011 1:43:42 PM - Gapped up today for a new all-time high. Prior mid-day reports noted - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line."
1/14/2011 1:24:11 PM - Enduring distributional pressure this week, pulling back toward prior highs and its 50 DMA line which define support to watch in the $106-107 area. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action indicative of prompt institutional support near its prior chart highs and 50 DMA line.
1/5/2011 2:10:47 PM - Hitting new all-time highs with a 2nd consecutive gain with above average volume, extended from any sound base. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines were swirling in late-October over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action noted -"Indicative of prompt institutional support near its prior chart highs and 50 DMA line."
10/25/2010 12:51:57 PM - Hovering near its all-time highs after a small gap up today. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system. Headlines last week were swirling over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm endured 2 big gaps down followed by a big gap up, with the rebound action noted -"Indicative of prompt institutional support near its prior chart highs and 50 DMA line."
10/20/2010 1:40:36 PM - Headlines are swirling over FDA approval of certain drugs while this Denmark-based Medical - Ethical Drug firm is having a wild week with 2 big gaps down followed by a big gap up today. The latest action is indicative of prompt institutional support near its prior chart highs and 50 DMA line. Noted in recent mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
10/13/2010 12:50:32 PM - This Denmark-based Medical - Ethical Drug firm is hovering at all-time highs. Noted in recent mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
10/4/2010 12:27:36 PM - This Denmark-based Medical - Ethical Drug firm gapped down today, following last week's surge to new all-time highs. Noted recently and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/30/2010 1:33:03 PM - This Denmark-based Medical - Ethical Drug firm recently surged to new all-time highs. Noted recently and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/29/2010 1:02:46 PM - This Denmark-based Medical - Ethical Drug firm is trading heavy volume yet again today with a gap up gain for another new all-time high. As noted recently, and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/28/2010 1:04:25 PM - This Denmark-based Medical - Ethical Drug firm is trading heavy volume again today and rallying to a new all-time high. As noted recently, and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/27/2010 1:05:43 PM - This Denmark-based Medical - Ethical Drug firm is churning a great deal of volume today at its all-time high. As noted recently, and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/9/2010 1:18:19 PM - This Denmark-based Medical - Ethical Drug firm gapped up today and hit a new all-time high. As noted 9/03/10 and in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
9/3/2010 1:17:48 PM - This Denmark-based Medical - Ethical Drug firm was noted in a few of July's mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
7/15/2010 1:19:21 PM - This Denmark-based Medical - Ethical Drug firm gapped up today and hit another new 52-week high. Noted in recent mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
7/14/2010 12:53:36 PM - This Denmark-based Medical - Ethical Drug firm has reached a new 52-week high today following a brief consolidation above its 50 DMA line. It had pulled back since gapping up and being noted in the 6/18 and 6/21 mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
7/1/2010 1:00:23 PM - This Denmark-based Medical - Ethical Drug firm is enduring distributional pressure today while consolidating just above its 50 DMA line. It has pulled back since gapping up and being noted in the 6/18 and 6/21 mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
6/30/2010 12:21:16 PM - This Denmark-based Medical - Ethical Drug firm has been quietly consolidating above its 50 DMA line, pulling back since gapping up and being noted in the 6/18 and 6/21 mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
6/28/2010 12:59:50 PM - This Denmark-based Medical - Ethical Drug firm has been quietly consolidating near May's all-time highs since gapping up and being noted in the 6/18 and 6/21 mid-day reports - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
6/21/2010 12:34:56 PM - This Denmark-based Medical - Ethical Drug firm gapped up for a second consecutive session today. Noted in 6/18/10 mid-day report - "It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system."
6/18/2010 12:44:33 PM - This Denmark-based Medical - Ethical Drug firm gapped up today, reaching a new all-time high just above its 5/03/10 peak. It has earned high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system.
6/16/2010 2:00:58 PM - This Denmark-based Medical - Ethical Drug firm sports high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system.
6/14/2010 12:54:18 PM - This Denmark-based Medical - Ethical Drug firm sports high ranks after demonstrating strong steady annual earnings (A criteria) growth. Quarterly comparisons show sales and earnings increases mostly below guidelines of the fact-based investment system.
1/10/2008 1:42:14 PM - Repaired its recent 50 DMA breach, and it may be forming a double bottom pattern. This Denmark based medical company sports high ranks after demonstrating strong steady earnings growth.
12/6/2007 1:20:40 PM - Gapped down. Gapped up on 12/04 to new all-time highs for a second day in a row, ut was noted as "Not near a proper technical buy point." This Denmark based medical company sports high ranks after demonstrating strong steady earnings and sale revenues growth.
12/5/2007 1:16:33 PM - Gapped up on 12/04 to new all-time highs for a second day in a row. Not near a proper technical buy point. This Denmark based medical company sports high ranks after demonstrating strong steady earnings and sale revenues growth.
12/4/2007 1:08:45 PM - Gapped up to a new all-time high for a second day in a row. Not near a proper technical buy point. This Denmark based medical company sports high ranks after demonstrating strong steady earnings and sale revenues growth.
12/3/2007 1:49:00 PM - Gapped up to a new all-time high, but not near a proper buy point. This Denmark based medical company sports high ranks after demonstrating strong steady earnings and sale revenues growth.
11/28/2007 - This Denmark based medical company sports high ranks after demonstrating strong steady earnings and sale revenues growth. It is not extended, and it found support near its 50 DMA line throughout its steady climb. Recent gains to new all-time highs lacked serious volume conviction.
11/21/2007 12:28:52 PM - This Denmark-based medical company sports high ranks, yet it is too extended from a sound base at this point.
10/31/2007 1:55:12 PM - This high-ranked leader has rallied for new all-time highs from a choppy base with a gain on above average volume after its latest strong earnings report.
10/2/2007 1:13:46 PM - Gains have been backed by unimpressive volume as it hit recent new highs. Sales history is below guidelines but it has shown strong earnings increases in the 3 latest quarterly reports. Weekly chart is marked by a few down weeks on above average volume versus only one up week on above average volume, which technically raises concerns. Its choppy chart pattern offers no sound buy point.
9/14/2007 1:10:17 PM - Gains backed by unimpressive volume as it hit new highs the past two days. Sales history is below guidelines but it has shown strong earnings increases in the 3 latest quarterly reports. Weekly chart is marked by a few down weeks on above average volume versus only one up week on above average volume, which technically raises concerns. Its choppy chart pattern offers no sound buy point.
9/10/2007 1:05:32 PM - Trading lower for a fourth consecutive session after a big 9/04/07 gap up gain on high volume. Sales history is below guidelines but it has shown strong earnings increases in the 3 latest quarterly reports. Weekly chart is marked by a few down weeks on above average volume versus only one up week on above average volume, which technically raises concerns. Its choppy chart pattern offers no sound buy point.
9/4/2007 12:45:54 PM - Gapped up to new highs today. Sales history is below guidelines but it has shown strong earnings increases in the 3 latest quarterly reports. Weekly chart is marked by a few down weeks on above average volume versus only one up week on above average volume, which technically raises concerns. Its choppy chart pattern offers no sound buy point.
8/28/2007 12:49:11 PM - Sales history is below guidelines but it has shown strong earnings growth or "C" criteria. Weekly chart is marked by a few down weeks on above average volume versus only one up week on above average volume, which technically raises concerns. Its choppy chart pattern offers no sound buy point.
8/8/2007 1:29:20 PM - Sales history is below guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.
8/7/2007 12:47:14 PM - Sales history is below guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.
8/6/2007 12:43:50 PM - Sales history is below guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.
5/2/2007 12:37:18 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
4/27/2007 12:39:11 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
4/26/2007 12:51:38 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
4/25/2007 12:49:53 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
4/24/2007 12:47:45 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
2/13/2007 12:57:47 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters. Plus no base.
2/12/2007 1:19:28 PM - "C" and sales history below guidelines. Current earnings per share ("C") should be up 25% or more and in many cases accelerating in recent quarters. Quarterly sales should also be up 25% or more or accelerating over prior quarters.
2/7/2007 1:26:43 PM - "C" and sales history below guidelines.
8/17/2004 1:00:00 PM - Best in pretty good group. Only trades 36,300 shares a day.